Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation

Experimental Hematology

Volumn 38, Issue 9, 2010, Pages 765-772

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; NILOTINIB; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN SK 9; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA CELL LINE; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

EID: 77955475487     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.04.017     Document Type: Article

References (28)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Thomas X., Danaïla C., Le Q.H., et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811-1822.
3. Pui C.H., Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007, 6:149-165.
4. Quintás-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848.
5. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
6. Mancini M., Scappaticci D., Cimino G., et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005, 105:3434-3441.
7. Pui C.-H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
8. Towatari M., Yanada M., Usui N., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104:3507-3512.
9. Fielding A.K., Richards S., Lazarus H.M., et al. Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood 2007, 110. Abstract 8.
10. Hofmann W.K., Jones L.C., Lemp N.A., et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99:1860-1862.
11. Kwiatkowski R.W., Lyamichev V., de Arruda M., et al. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 1999, 4:353-364.
12. Okabe S., Tauchi T., Ohyashiki K., Broxmeyer H.E. Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45. Blood Cells Mol Dis 2006, 36:308-314.
13. Okabe S., Fukuda S., Kim Y.J., et al. Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood 2005, 105:474-480.
14. Okabe S., Tauchi T., Nakajima A., et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007, 16:503-514.
15. Kawasaki E.S., Clark S.S., Coyne M.Y., et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A 1988, 85:5698-5702.
16. Kwok P.Y. SNP genotyping with fluorescence polarization detection. Hum Mutat 2002, 19:315-323.
17. de Arruda M., Lyamichev V.I., Eis P.S., et al. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev Mol Diagn 2002, 2:487-496.
18. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27:469-471.
19. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007, 109:3189-3197.
20. Oda T., Heaney C., Hagopian J.R., et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994, 269:22925-22928.
21. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
22. White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005, 106:2520-2526.
23. La Rosée P., Holm-Eriksen S., Konig H., et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 2008, 93:765-769.
24. Weisberg E., Manley P.W., Cowan-Jacob S.W., et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345-356.
25. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
26. Quintás-Cardama A., Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008, 14:4392-4399.
27. Giles F.J., Cortes J., Jones D., et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
28. Koldehoff M., Kordelas L., Beelen D.W., et al. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 2010, 95:388-397.